# Cosmos Health Inc.: overview COSM · Nasdaq · CIK 1474167 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cosm.md) · [Financials](/companies/cosm/financials.md) · [Filings](/companies/cosm/filings.md) · [Insiders](/companies/cosm/insiders.md) Latest reported revenue: [$19.0m](/filings/0001477932-26-005146.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 18, 2026 (XBRL us-gaap:Revenues, accession 0001477932-26-005146). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [12.4](/filings/0001477932-25-008322.md) | [14.2 d](/filings/0001477932-26-002278.md) | [13.7](/filings/0001477932-26-003357.md) | [14.7](/filings/0001477932-26-005146.md) | [17.1](/filings/0001477932-25-008322.md) | [19.7 d](/filings/0001477932-26-002278.md) | [17.9](/filings/0001477932-26-003357.md) | [19.0](/filings/0001477932-26-005146.md) | | Gross margin | % | [9.7%](/filings/0001477932-25-008322.md) | [7.1% d](/filings/0001477932-26-002278.md) | [14.9%](/filings/0001477932-26-003357.md) | [7.9%](/filings/0001477932-26-005146.md) | [15.2%](/filings/0001477932-25-008322.md) | [10.6% d](/filings/0001477932-26-002278.md) | [7.7%](/filings/0001477932-26-003357.md) | [8.0%](/filings/0001477932-26-005146.md) | | Operating margin | % | [(18.0%)](/filings/0001477932-25-008322.md) | [(63.0%) d](/filings/0001477932-26-002278.md) | [(6.1%)](/filings/0001477932-26-003357.md) | [(17.9%)](/filings/0001477932-26-005146.md) | [(10.6%)](/filings/0001477932-25-008322.md) | [(57.9%) d](/filings/0001477932-26-002278.md) | [(12.2%)](/filings/0001477932-26-003357.md) | [(15.4%)](/filings/0001477932-26-005146.md) | | Net margin | % | [(67.5%)](/filings/0001477932-25-008322.md) | [(23.5%) d](/filings/0001477932-26-002278.md) | [(6.0%)](/filings/0001477932-26-005146.md) | [(19.2%)](/filings/0001477932-26-005146.md) | [(31.3%)](/filings/0001477932-25-008322.md) | [(51.5%) d](/filings/0001477932-26-002278.md) | [(15.6%)](/filings/0001477932-26-005146.md) | [(32.1%)](/filings/0001477932-26-005146.md) | | Diluted EPS | $ per share | [(0.45)](/filings/0001477932-25-008322.md) | not reported | [(0.03)](/filings/0001477932-26-003357.md) | [(0.10)](/filings/0001477932-26-005146.md) | [(0.17)](/filings/0001477932-25-008322.md) | not reported | [(0.06)](/filings/0001477932-26-003357.md) | [(0.10)](/filings/0001477932-26-005146.md) | | Free cash flow | $m | [0.5 d](/filings/0001477932-25-008322.md) | [(3.9) d](/filings/0001477932-26-002278.md) | [(0.2)](/filings/0001477932-26-003357.md) | [(1.2) d](/filings/0001477932-26-005146.md) | [(2.5) d](/filings/0001477932-25-008322.md) | [(4.6) d](/filings/0001477932-26-002278.md) | [(1.1)](/filings/0001477932-26-003357.md) | [(1.8) d](/filings/0001477932-26-005146.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [56.2](/filings/0001477932-23-002443.md) | [50.3](/filings/0001477932-24-004545.md) | [53.4](/filings/0001477932-25-002759.md) | [54.4](/filings/0001477932-26-002278.md) | [65.3](/filings/0001477932-26-002278.md) | | Gross margin | % | [14.8%](/filings/0001477932-23-002443.md) | [11.8%](/filings/0001477932-24-004545.md) | [8.1%](/filings/0001477932-25-002759.md) | [7.9%](/filings/0001477932-26-002278.md) | [12.1%](/filings/0001477932-26-002278.md) | | Operating margin | % | [(8.1%)](/filings/0001477932-23-002443.md) | [(14.8%)](/filings/0001477932-24-004545.md) | [(40.9%)](/filings/0001477932-25-002759.md) | [(28.6%)](/filings/0001477932-26-002278.md) | [(25.6%)](/filings/0001477932-26-002278.md) | | Net margin | % | [(14.2%)](/filings/0001477932-23-002443.md) | [(27.5%)](/filings/0001477932-24-004545.md) | [(34.7%)](/filings/0001477932-25-002759.md) | [(29.7%)](/filings/0001477932-26-002278.md) | [(29.3%)](/filings/0001477932-26-002278.md) | | Diluted EPS | $ per share | [(23.74)](/filings/0001477932-23-002443.md) | [(33.16)](/filings/0001477932-24-004545.md) | [(2.15)](/filings/0001477932-25-002759.md) | [(1.17)](/filings/0001477932-26-002278.md) | [(0.63)](/filings/0001477932-26-002278.md) | | Free cash flow | $m | [(7.7)](/filings/0001477932-23-002443.md) | [(14.9)](/filings/0001477932-24-004545.md) | [(16.9)](/filings/0001477932-25-002759.md) | [(8.1)](/filings/0001477932-26-002278.md) | [(8.5)](/filings/0001477932-26-002278.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cosm/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $110.0k | 594,462 | | Added +581,728 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $61.8k | 333,842 | | Added +238,107 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $53.4k | 289,287 | | New +289,287 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $52.1k | 282,094 | | Reduced −36,017 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $49.5k | 267,797 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $33.6k | 182,100 | Call | Reduced −114,200 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $32.2k | 173,966 | | Added +33,959 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $10.0k | 53,887 | | Added +33,333 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $8.4k | 45,243 | | Unchanged | | [Sassicaia Capital Advisers LLC](/funds/1692751.md) | 2026-06-30 | $6.6k | 36,000 | | New +36,000 | ## Recent filings [All 635 filings](/companies/cosm/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-22 | 11:50 ET | [8-K](/filings/0001477932-26-006396.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001477932-26-006396 | | 2026-10-09 | 17:00 ET | [8-K](/filings/0001477932-26-006158.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001477932-26-006158 | | 2026-08-20 | 17:11 ET | [8-K](/filings/0001477932-26-005195.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001477932-26-005195 | | 2026-08-18 | 16:31 ET | [10-Q](/filings/0001477932-26-005146.md) | Quarterly report, period 2026-06-30 | 0001477932-26-005146 | | 2026-07-16 | 16:35 ET | [8-K](/filings/0001477932-26-004357.md) | 3.03 Change to security holders’ rights; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001477932-26-004357 | | 2026-07-06 | 09:30 ET | [8-K](/filings/0001477932-26-004192.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001477932-26-004192 | | 2026-06-02 | 16:30 ET | [DEF 14A](/filings/0001477932-26-003588.md) | Proxy statement, period 2026-06-02 | 0001477932-26-003588 | | 2026-05-22 | 09:30 ET | [8-K](/filings/0001477932-26-003403.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001477932-26-003403 | | 2026-05-20 | 16:31 ET | [10-Q](/filings/0001477932-26-003357.md) | Quarterly report, period 2026-03-31 | 0001477932-26-003357 | | 2026-04-16 | 11:15 ET | [8-K](/filings/0001477932-26-002316.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001477932-26-002316 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001477932-26-002278.md), filed Apr 15, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1474167 - Tickers: COSM - Exchange: Nasdaq - SIC code: 5122 Wholesale-Drugs, Proprietaries & Druggists' Sundries - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 16:09 ET. No prices; not investment advice.